Although not targeting sarcoma, anti-CD19 CAR-NK cells developed recently for relapsed or refractory anti-CD19-positive cancers have shown great clinical responses when produced from selected KIR-HLA mismatched cord-blood units (49). Here, CD19 is linked to sarcoma.